Articles from Infinimmune

Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced a research collaboration agreement with Immunome, Inc. (NASDAQ: IMNM) for the discovery and optimization of novel antibodies. Under the agreement, Immunome will receive target exclusivity. Financial terms of the deal were not disclosed.

Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced the launch of GLIMPSE-1, a protein language model trained solely on native human antibody sequences. Developed using millions of paired heavy and light chains from human memory B cells, GLIMPSE-1 represents a new paradigm for therapeutic antibody engineering that applies the design principles of the human adaptive immune system.

Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, announced today the appointment of Tim Sullivan, Ph.D., as Chief Business Officer. In this newly created role, Dr. Sullivan, who has decades of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development initiatives, as well as corporate and product strategic planning.

Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, announced today the appointment of a new independent director, Neela Patel, Ph.D., to the company's Board of Directors. Dr. Patel is a seasoned life sciences executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong drug development expertise, including a track record of successful U.S. and global pharmaceutical licensing deals.

Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, today announced a partnership with Grid Therapeutics (“Grid”), a clinical stage biotechnology company that focuses on human-derived antibodies, to collaborate in identifying new antibody drug candidates for non-small cell lung cancer.

Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, today announced that it has closed a $12 million seed round led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier.